Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, with a focus on a Phase 3-ready drug for chronic kidney disease. Alpine’s lead program is a fusion protein called povetacicept, which has shown promising results in reducing proteinuria and hematuria in patients with IgA nephropathy. The drug targets B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL), making it unique in its approach. The acquisition comes as Vertex aims to expand its pipeline with potentially groundbreaking treatments for various immunological disorders. The deal is expected to close later this quarter, bringing povetacicept into Vertex’s expanding portfolio of kidney disease therapies.
Source link
Vertex Pharma Bolsters Immunology Profile With $4.9B Alpine Immune Sciences Acquisition
